MétaCan
Menu
Back to cohort
Record W4416093687 · doi:10.1111/dom.70289

Effects of <scp>SGLT2</scp> inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

2025· article· en· W4416093687 on OpenAlexafffund
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad

Bibliographic record

VenueDiabetes Obesity and Metabolism · 2025
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsMcGill University Health Centre
FundersJanssen Research and DevelopmentCanadian Institutes of Health ResearchRaymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale UniversityFundação para a Ciência e a TecnologiaBoehringer IngelheimMcGill UniversityYale UniversityEli Lilly and Company
KeywordsAlbuminuriaPooled analysisMeta-analysisKidney diseaseKidneyClinical trial

Abstract

fetched live from OpenAlex

BACKGROUND: Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co-transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD). Patients with low- or without albuminuria have been underrepresented in randomised clinical trials (RCTs), and the effects of SGLT2i on cardiovascular and kidney outcomes across the full range of albuminuria require further investigation. AIMS: To study the effects of SGLT2i on kidney and cardiovascular outcomes across albuminuria levels in populations with different cardiovascular-kidney-metabolic (CKM) risk. METHODS: Individual-patient data pooled analysis of RCTs across the CKM spectrum. Outcomes were studied across urinary albumin-to-creatinine ratio (UACR) both as categorical and continuous variables using survival and mixed effects models. RESULTS: ) baseline UACR was 28 (8-240) mg/g: 13 669 (51.1%) had UACR <30 mg/g, 6904 (25.8%) UACR 30-300 mg/g, and 6177 (23.1%) UACR >300 mg/g. Compared to patients with lower UACR, those with higher UACR were younger, with a more frequent history of hypertension, diabetes, and obesity, and lower eGFR. UACR was linearly associated with kidney and cardiovascular outcomes as well as mortality. Compared to placebo, SGLT2i reduced the risk of kidney events, HF hospitalisations, atherothrombotic events, cardiovascular and all-cause mortality across the full UACR spectrum (Pinteraction >0.1 for all outcomes). Compared to placebo, SGLT2i reduced albuminuria levels by 13%, on average: gMratio 0.87, 95%CI 0.85-0.88, p < 0.001. CONCLUSIONS: Higher albuminuria was associated with an increased risk of cardiovascular and kidney outcomes. SGLT2i improved cardiovascular and kidney outcomes across the full range of albuminuria, including normo-albuminuria.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.028
metaresearch head score (Gemma)0.034
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.028
Threshold uncertainty score0.149

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0280.034
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0200.044
Bibliometrics0.0030.003
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0010.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.254
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueDiabetes Obesity and MetabolismSame topicDiabetes Treatment and ManagementFrench-language works237,207